INNOVATIVE TECHNOLOGY FOR MAXIMUM CLINICAL EFFICACY AND VERSATILITY

The EX-308 handpiece features a continuously adjustable spot size from 18 mm² to 2 mm round, with constant fluence. Operators can adjust the size and shape of the beam, even while dosing, and deliver a consistent dose. Arms, legs, and back are quickly treated with the largest spot size, while the small 2 mm spot allows precision treatments of the face, neck, and scalp.

A brightly lit aiming beam corresponds to the size and shape of the dose-delivery beam for easy, accurate, and rapid targeted treatments.

The dose-delivery beam has a flat-top profile for uniform dosing and clearance. Collimation eliminates surface scatter and facilitates therapeutic penetration of the 308 nm for maximum clinical efficacy.

Weighing about 100 lbs, the EX-308 is small enough for any treatment room and is easily portable.

EX-308 TECHNICAL SPECIFICATIONS

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Specification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wavelength</td>
<td>308 nm ± 1 nm</td>
</tr>
<tr>
<td>Max Pulse Repetition Rate</td>
<td>150 Hz</td>
</tr>
<tr>
<td>Max Output Power</td>
<td>2.25 W</td>
</tr>
<tr>
<td>Delivery</td>
<td>1.5 m Liquid Filled Fiber Optic</td>
</tr>
<tr>
<td>Fiber Life</td>
<td>25 Million Shots, User Replaceable</td>
</tr>
<tr>
<td>Beam Size</td>
<td>Continuously Adjustable from 18 mm² to 2 mm</td>
</tr>
<tr>
<td>Operating Modes</td>
<td>Intermittent, Continuous, Custom</td>
</tr>
<tr>
<td>Electrical Inputs</td>
<td>115 VAC, 6 A, 47 Hz to 63 Hz</td>
</tr>
<tr>
<td>Gas</td>
<td>XeHCl Mix</td>
</tr>
<tr>
<td>Gas Life</td>
<td>Approximately 1 Year</td>
</tr>
<tr>
<td>Mirror Life</td>
<td>25 Million Shots</td>
</tr>
<tr>
<td>Weight</td>
<td>48 kg (106 lbs)</td>
</tr>
<tr>
<td>Size</td>
<td>36 cm wide x 68 cm long x 82 cm tall (14” x 27” x 32”)</td>
</tr>
<tr>
<td>Warranty</td>
<td>1 year</td>
</tr>
</tbody>
</table>

EX-308 manufactured and distributed under license from Surgilight, Inc. Federal law restricts this device to sale by or on the order of a physician. Product specifications are subject to change without notice. © 2005 Ra Medical Systems, Inc. All rights reserved.
PATIENTS BENEFIT.
The EX-308 safely delivers precisely targeted, high-dose 308-nm UVB to lesions without exposing healthy skin. Patients enjoy fast clearing and long remissions after 6 to 10 treatments for psoriasis and about 25 sessions for vitiligo. Treatments take only a few minutes twice each week. Typical psoriasis remission is 4 to 6 months. Positive outcomes after very few treatments encourage patient compliance and enhance satisfaction.

Clinical studies have shown:
- 84% of psoriasis patients have 75% clearing in 6 to 10 sessions.\(^1\)
- Clearing of stubborn psoriatic lesions occurs rapidly and safely.\(^2\)
- After 2 to 4 weeks of thrice weekly treatments, the degree of vitiligo repigmentation is higher than with any other therapy.\(^3\)
- Slightly more than 50% of the vitiligo patients showed 75% or more pigmentation after 30 treatments or less.\(^4\)

308NM EXCIMER LASER THERAPY IS CLINICALLY PROVEN AND PEER-REVIEWED

PSORIASIS

VITILIGO

PRACTICE PROFITS.
Therapy with the EX-308 is widely reimbursed under laser-specific codes at about three to four times the standard phototherapy rates. Carriers including Aetna; Cigna; UnitedHealthcare; the Blue Cross Blue Shield Plans of WellPoint, Carefirst, Regence, Empire, and Independence; and Medicare have published policies approving excimer laser treatment for psoriasis. As most treatment regimens consist of about 10 to 25 treatments, depending on the condition, the EX-308 generates recurring revenue for your practice.
The EX-308 is both affordable and profitable for your practice. There is no fee-for-service or revenue sharing. Treating just 1 patient each month generally covers your lease. Treating just 4 patients each month means less than a 1-year payback period.

Your practice profits from widespread reimbursement, recurring revenue, and high return on investment.

Taneja et al. 308-nm Excimer Laser for the Treatment of Psoriasis: Induration-Based Dosimetry. Archives of Dermatology. 2003;139:769-76.\(^4\)

